1254885-39-6

Minnelide (injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily) free base leads to a marked decrease in tumor weight and volume at the end of treatment and increases survival in orthotopic model of pancreatic cancer with MIA PaCa-2–derived human pancreatic tumors^[2]. Minnelide (injection intraperitoneally; 0.42 mg/kg; once daily; 28 days) free base prevents locoregional spread and leads to a decrease in average tumor weight in a xenograft model of pancreatic cancer with metastatic S2-013 cells^[2]. Minnelide (injection intraperitoneally; 0.42 mg/kg, 0.21 mg/kg; once daily) free base causes tumor regression and tumors from Minnelide-treated animals showed fibrosis and the presence of pyknotic nuclei in human pancreatic cancer xenografts in SCID mice^[2].